The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial

The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial

Objectives: To evaluate the immunogenicity of an extended interval regimen of BNT162b2 among healthy school-age children. Methods: A randomized-control trial conducted among healthy Thai children aged 5-11 years. Participants received two doses of BNT162b2 with an 8-week (extended dosing) vs 3-week...

Full description

Bibliographic Details
Main Authors: Napaporn Chantasrisawad, Chonnamet Techasaensiri, Pope Kosalaraksa, Wanatpreeya Phongsamart, Auchara Tangsathapornpong, Peera Jaru-Ampornpan, Jiratchaya Sophonphan, Piyarat Suntarattiwong, Thanyawee Puthanakit
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:International Journal of Infectious Diseases
Subjects:
SARS-CoV-2
BNT162b2
COVID-19 vaccine
Dosing interval
Antibody
Children
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971223000668

Similar Items

Similar Items